FOLH1 and xerostomia: The focus was directed toward PSMA and ACP3, with the objective to identify ligands with adequate tumor‐targeting profiles, thereby mitigating off‐target effects often observed with PSMA‐targeting agents, such as renal toxicity and xerostomia.[21, 47] From the PSMA screenings, A3113/B423 emerged as the most enriched and selective combination for PSMA compared to GCP3.